OverviewChartNewsTraderScreen

HSBC Call 598.466 22UA 15.01.2025/  DE000HG1J8P7  /

EUWAX
5/15/2024  3:00:21 PM Chg.0.000 Bid5/15/2024 Ask5/15/2024 Underlying Strike price Expiration date Option type
0.001EUR 0.00% 0.001
Bid Size: 150,000		 0.031
Ask Size: 150,000		 BIONTECH SE SPON. AD... 598.4658 - 1/15/2025 Call
TeleTrader 5/6 BioNTech's Q1 revenue slumps 85% to €187.6M
GlobeNewswire 5/6 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 4/22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 4/7 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
TeleTrader 3/20 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 3/20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 3/20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 3/11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 3/7 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 3/6 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 2/8 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 1/31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 1/22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
TeleTrader 1/9 BioNTech sees $3.3B revenue for 2024, expanding into oncology
GlobeNewswire 1/9 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 12/21/2023 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 12/18/2023 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 12/12/2023 BioNTech to Inaugurate First African Site on December 18, 2023
TeleTrader 11/6/2023 BioNTech Q3 revenue plummets 74% to €895M
GlobeNewswire 11/6/2023 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire 10/26/2023 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire 10/23/2023 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...
GlobeNewswire 10/23/2023 BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to ...
GlobeNewswire 10/19/2023 BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial wit...
GlobeNewswire 10/16/2023 BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023